Singaporean biotech startup, Tessa Therapeutics, is set for liquidation after unsuccessful attempts to attract further investment or secure a strategic buyer amid a market downturn. The high-profile closure leaves a lasting impact on Singapore’s burgeoning biotech industry. State-linked funds Temasek and EDBI are investors in the company.